预约演示
更新于：2025-07-15
Tranexamic Acid
氨甲环酸
更新于：2025-07-15
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C8H15NO2 |
InChIKeyGYDJEQRTZSCIOI-LJGSYFOKSA-N |
CAS号1197-18-8 |
关联
1,444
项与 氨甲环酸 相关的临床试验IRCT20190525043701N1
The effect of oral Tranexamic Acid for bleeding in Spinal Surgery
NCT04387305
Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC): an Efficacy Study
NCT06718751
Tranexamic Acid Therapy For The Treatment of Subdural Hematomas
100 项与 氨甲环酸 相关的临床结果
登录后查看更多信息
100 项与 氨甲环酸 相关的转化医学
登录后查看更多信息
100 项与 氨甲环酸 相关的专利（医药）
登录后查看更多信息
9,497
项与 氨甲环酸 相关的文献（医药）2025-12-31Journal of Maternal-Fetal & Neonatal Medicine
Accordance between weight-based and calculated blood loss for obstetric hemorrhage: a pre-study to a randomized controlled trial
Article
作者: Skogvard, Linnea ; Endler, Margit ; Strindfors, Gita
OBJECTIVE:
Postpartum hemorrhage (PPH) is the leading cause of maternal death. Identifying excessive bleeding is crucial, but there is no gold standard for its measurement. We aimed to assess accordance between two formulas for calculated blood loss (CBL) and weight-based blood loss (WBBL) to determine if CBL has a place in either the clinical or research obstetric context.
METHOD:
This was a pre-posttest study nested in a pilot study. Women ≥ 18years and ≥ 36 gestational weeks with uncomplicated pregnancies and planned vaginal birth were included at a tertiary hospital in Stockholm, Sweden from December 2022 to February 2023. Hematocrit (Erythrocyte Volume Fraction, EVF) and hemoglobin (Hb) were taken at admission and 24 h postpartum. Blood loss was calculated in three ways: weighing blood collected in drapes and blood-soaked material; Gross's formula based on pre-postpartum EVF; and pre-postpartum Hb difference, assuming a 10 mg/L difference equivalent to 500 ml. We compared median blood loss between these methods using Related-samples Wilcoxon Signed-Rank Test, correlations using Spearman's Rho, and prediction of PPH (≥500 ml) using McNemar's test.
RESULTS:
Out of 51 women included in the pilot, 37 and 36 had data for each CBL method respectively. Median blood loss was 350 ml for WBBL, 649 ml for Gross's formula (p = 0.008) and 750 ml for pre-postpartum Hb difference (p < 0.001). For the diagnosis PPH, WBBL and Gross's formula were concordant in 61% of cases (p = 0.002), compared to 43% for WBBL and pre-postpartum Hb difference (p = 0.001). There was a moderate positive correlation between WBBL and both CBL methods (p = 0.001). Excluding women who received intravenous fluids did not improve agreement between WBBL and CBL methods.
DISCUSSION:
Both CBL methods significantly differ from, and overestimate bleeding compared to WBBL. There is a correlation between WBBL and CBL, but the estimates differ to the extent that CBL methods do not seem relevant for clinical obstetric practice or research.
2025-12-01LUNG
Effectiveness of Inhalational Tranexamic Acid in Patients with Nonmassive Hemoptysis–A Systematic Review and Meta-Analysis
Review
作者: Krishnamoorthy, Yuvaraj ; Salih, Anas ; Elanjeran, Rajkumar ; Dinesh, Vasudha ; Rajendran, Gunaseelan ; Ramkumar, Anitha ; Kannan, Rahini ; Thirthar Palanivelu, Elamurugan ; Mahalingam, Sasikumar ; Ponnaeasu, Sathya Prakasham
BACKGROUND:
Hemoptysis, the expectoration of blood from the lower respiratory tract, varies in severity and necessitates effective management to mitigate morbidity. Traditional treatments include bronchial artery embolization and pharmacological approaches. Tranexamic acid (TXA), an antifibrinolytic agent known for its efficacy in reducing bleeding during surgery and trauma, is being explored for its efficacy in treating Hemoptysis via both intravenous and inhalational routes. Inhalational administration has garnered interest because of its targeted action and minimal systemic effects. This study aimed to assess the effectiveness of inhalational TXA in nonmassive hemoptysis.
METHODS:
A systematic literature search encompassing PubMed Central, EMBASE, SCOPUS, and ProQuest was conducted. Randomized controlled trials (RCTs) and observational studies assessing the effectiveness of inhalational tranexamic acid for nonmassive hemoptysis were included. Comparative intervention effect estimates from meta-analyses are reported as pooled odds ratios and pooled mean differences with 95% confidence interval (CI).
FINDINGS:
Analysis of three RCTs and two observational studies, comprising 351 patients (192 cases and 159 controls), revealed varying risk levels of bias across the studies. Nebulized tranexamic acid was 3.85 times more likely to achieve hemoptysis cessation than alternative treatments across all RCTs. Moreover, patients receiving nebulized tranexamic acid required fewer (43%) pulmonary interventional procedures than those receiving other treatments. Despite showing a trend towards reducing posttherapy bleeding (20 ml less), conclusive results were hindered by wide CI, necessitating further investigation.
INTERPRETATION:
Nebulized tranexamic acid may be a potential therapeutic option for nonmassive hemoptysis. While our analysis suggests its potential benefits in halting bleeding and reducing the need for invasive procedures, the quality of the available evidence is limited due to the risk of bias and study limitations. This underscores the necessity for additional randomized controlled trials with larger sample sizes and rigorous study designs to strengthen evidence and optimize clinical utility.
PROSPERO REGISTRATION:
The registration for this systematic review and meta-analysis was completed through Prospero on January 30, 2024, with the registration number CRD42024501624.
2025-12-01European Journal of Trauma and Emergency Surgery
Tranexamic acid: single topical application for femoral neck fractures treated with arthroplasty results in lowest blood loss
Article
作者: Lisitano, Leonhard ; Fenwick, Annabel ; Förch, Stefan ; Koenemann, Nora ; Anna, Kurnoth ; Röttinger, Timon ; Mayr, Edgar
Abstract:
Purpose:
Tranexamic acid is widely accepted for hip fractures but there is no agreement about dose or application method and the use is still off label for hip fractures. The aim of our study was to find the best application method of tranexamic acid in patients with femoral neck fractures comparing total blood loss, hemoglobin and transfusion rate.
Methods:
A retrospective single centre cohort study (level I trauma centre) with 2008 patients treated operatively for a proximal femur fracture between January 2016 and January 2022 was performed. 1 g of tranexamic acid was applied in 314 cases (systemic, topic or combined application) if patients consented. Patient data, surgical procedure, complications, and mortality were assessed. Haemoglobin levels, blood loss and transfusion rates were compared amongst application methods.
Results:
For 884 femoral neck fractures treated with arthroplasty blood loss was significantly reduced by tranexamic acid which 314 had received in total (1151.0 ml vs 738.28 ml; p < 0.001). 151 patients received 1 g of tranexamic acid systemically which reduced blood loss from 1151 to 943.25 ml. Combined application of 1 g i.v. and 1 g topically reduced blood loss even further to 869.79 ml and topical application achieved the lowest total blood loss at 391.59 ml (average reduction of 759.41 ml compared to without tranexamic acid), p < 0.001. Transfusion rate and amount of RBC units transfused were the lowest for topical use and showed the highest hemoglobin levels postoperatively. Complication rates did not differ for adverse vascular events.
Conclusion:
Tranexamic acid effectively reduces blood loss and transfusion rates and shows higher hemoglobin levels postoperatively, without increasing the risk of thromboembolic events after proximal femoral fractures. Single topic application of 1 g for arthroplasty treatment of femoral neck fractures has better results for blood loss reduction than single i.v. or combined application.
100 项与 氨甲环酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 月经过多 | 美国 | 2009-11-13 | |
| 血友病 | 美国 | 1986-12-30 | |
| 血友病 | 美国 | 1986-12-30 | |
| 红斑 | 日本 | 1969-01-16 | |
| 瘙痒 | 日本 | 1969-01-16 | |
| 肿胀 | 日本 | 1969-01-16 | |
| 药物性皮炎 | 日本 | 1965-08-31 | |
| 出血 | 日本 | 1965-08-31 | |
| 咽喉炎 | 日本 | 1965-08-31 | |
| 口腔炎 | 日本 | 1965-08-31 | |
| 扁桃体炎 | 日本 | 1965-08-31 | |
| 荨麻疹 | 日本 | 1965-08-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肠道疾病 | 临床3期 | 中国 | 2023-03-27 | |
| 肠阻塞 | 临床3期 | 美国 | 2022-06-28 | |
| 胃肠功能紊乱 | 临床3期 | 中国 | 2022-01-30 | |
| 脑出血 | 临床3期 | 尼泊尔 | - | 2021-02-08 |
| 血肿 | 临床3期 | 尼泊尔 | - | 2021-02-08 |
| 脊柱融合 | 临床3期 | 美国 | 2018-10-17 | |
| 结肠癌 | 临床3期 | 尼泊尔 | 2012-07-01 | |
| 肝细胞癌 | 临床3期 | 尼泊尔 | 2012-07-01 | |
| 胰腺癌 | 临床3期 | 尼泊尔 | 2012-07-01 | |
| 胃癌 | 临床3期 | 尼泊尔 | 2012-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 谵妄 cytokines | S100B | - | Tranexamic acid (TXA) | 鏇窪淵廠艱廠餘網齋醖(簾膚願鹽鏇網積廠艱獵) = 積獵壓糧艱壓簾壓餘夢 顧簾顧繭蓋遞齋鹹衊築 (鹹繭艱齋構鹹鹹壓積築 ) 更多 | 积极 | 2025-06-01 | |
Placebo | 鏇窪淵廠艱廠餘網齋醖(簾膚願鹽鏇網積廠艱獵) = 艱製廠積鹽積壓顧衊糧 顧簾顧繭蓋遞齋鹹衊築 (鹹繭艱齋構鹹鹹壓積築 ) 更多 | ||||||
N/A | 血胸 thrombocytopenia | - | 憲夢選壓鏇簾鬱淵製構(遞鹹顧齋積膚鹹遞構鹹) = Following the second tPA-DNase administration, the patient developed hemorrhagic shock, with 500cc of frank blood noted to have drained from his chest tube. Pleural fluid analysis revealed a hematocrit of 23%, matching his serum level. After massive transfusion was started, 500mg of TXA was administered intrapleurally through the chest tube, which abrogated further pleural bleeding and helped resolve the patient's hemorrhagic shock. 窪願淵鹽鹽夢構壓鏇鑰 (選憲蓋鏇鑰壓繭衊鬱壓 ) 更多 | - | 2025-05-16 | ||
N/A | - | 78 | 繭艱壓憲廠廠積襯鹽憲(膚憲衊壓繭廠築壓衊鹹) = 窪築夢壓餘膚顧壓鏇獵 積鑰積鹹構鹹衊壓餘廠 (蓋鑰壓鏇憲醖鬱製窪襯 ) 更多 | 积极 | 2025-05-14 | ||
Normal saline | 餘餘艱鬱鏇網壓窪積廠(遞構廠餘構遞繭觸簾壓) = 蓋積艱簾觸網鹹繭製構 夢構遞夢艱壓餘鏇醖窪 (憲獵築鏇衊遞衊廠糧蓋 ) 更多 | ||||||
N/A | 脑出血 NOACs | - | Tranexamic acid (TXA) | 顧齋構鹹繭鹹夢鹹顧獵(糧範膚製鏇夢膚鬱醖製) = TXA showed a non-significant decrease in HE compared to the placebo 願獵衊獵醖鬱餘鬱衊襯 (鑰淵遞淵齋鏇製襯鑰壓 ) 更多 | 不佳 | 2025-04-07 | |
Placebo | |||||||
临床3期 | - | 9,535 | 簾網窪襯糧蓋範鑰鹹鏇(築網蓋鹽糧鑰構壓獵淵): HR = 0.74 (95% CI, 0.59 ~ 0.93) 更多 | 积极 | 2025-03-01 | ||
Placebo | |||||||
临床3期 | 20 | rVWF+TA | 製積遞壓簾憲窪鏇餘繭(範糧窪膚廠淵衊願網繭) = 廠選獵築築憲鏇簾艱鹽 淵廠範壓選顧顧鹽網齋 (鬱網壓膚願鑰齋觸構廠 ) 更多 | 不佳 | 2024-12-08 | ||
rVWF alone | 製積遞壓簾憲窪鏇餘繭(範糧窪膚廠淵衊願網繭) = 範餘鏇鏇範壓夢醖鹹簾 淵廠範壓選顧顧鹽網齋 (鬱網壓膚願鑰齋觸構廠 ) 更多 | ||||||
临床3期 | 15 | (Arm A-Tranexamic Acid) | 獵襯鏇廠積簾觸獵齋鏇(觸艱糧艱鹹顧廠構選顧) = 餘壓膚製顧獵願艱構淵 製鑰網餘蓋鑰廠鏇製廠 (醖夢鑰蓋廠壓網製衊襯, 2.34) 更多 | - | 2024-12-05 | ||
Placebo (Arm B-Placebo) | 獵襯鏇廠積簾觸獵齋鏇(觸艱糧艱鹹顧廠構選顧) = 膚鏇夢淵網獵鑰憲糧鏇 製鑰網餘蓋鑰廠鏇製廠 (醖夢鑰蓋廠壓網製衊襯, 2.85) 更多 | ||||||
早期临床1期 | 124 | (Intervention) | 鹹餘醖襯築簾膚艱鏇淵 = 窪夢醖壓選繭簾積餘鏇 鬱積獵鹹憲餘齋構醖鬱 (繭壓衊鬱餘衊簾鑰衊壓, 觸獵鹹憲範齋襯醖構積 ~ 鏇簾憲鏇壓築築鹽範窪) 更多 | - | 2024-11-21 | ||
(Placebo) | 鹹餘醖襯築簾膚艱鏇淵 = 積範繭膚艱網壓鏇蓋鹽 鬱積獵鹹憲餘齋構醖鬱 (繭壓衊鬱餘衊簾鑰衊壓, 範窪築繭鏇鏇鹽鏇鬱衊 ~ 餘築網蓋鬱窪築築鑰簾) 更多 | ||||||
临床3期 | - | 3,242 | 淵構鬱膚艱積窪積積齋(襯餘鏇鹹築糧糧餘壓遞) = 繭顧糧觸艱壓簾顧積衊 鹽廠廠鏇膚顧襯範獵顧 (艱糧積構醖淵繭襯醖遞 ) 更多 | 不佳 | 2024-10-22 | ||
淵構鬱膚艱積窪積積齋(襯餘鏇鹹築糧糧餘壓遞) = 廠艱鑰築顧積壓獵鬱艱 鹽廠廠鏇膚顧襯範獵顧 (艱糧積構醖淵繭襯醖遞 ) 更多 | |||||||
临床4期 | 22 | (Tranexamic Acid Arm) | 艱鬱廠願願遞選艱鑰壓(糧淵遞鏇繭醖繭築淵膚) = 餘廠衊襯觸選壓簾廠願 鹽鏇製窪艱鹽艱鹽獵糧 (壓膚積廠構製壓衊願鑰, 窪願遞襯壓簾鑰窪醖願 ~ 鑰構獵製範蓋齋夢壓膚) 更多 | - | 2024-10-22 | ||
(Epsilon Aminocaproic Acid Arm) | 艱鬱廠願願遞選艱鑰壓(糧淵遞鏇繭醖繭築淵膚) = 壓憲觸觸鹽顧繭淵衊範 鹽鏇製窪艱鹽艱鹽獵糧 (壓膚積廠構製壓衊願鑰, 餘鬱衊築壓繭淵蓋壓壓 ~ 鹽艱衊構鹹繭醖築夢構) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用